Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect
Amyotrophic lateral sclerosis has been a tough area for drug research, but Eli Lilly has been spreading its bets in ...
Amyotrophic lateral sclerosis has been a tough area for drug research, but Eli Lilly has been spreading its bets in ...
Indianapolis-based pharmaceutical behemoth Eli Lilly has filed lawsuits against four compounders claiming that they sold unapproved products that contain tirzepatide, ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
The next wave of metabolic medicines in development includes oral GLP-1 drugs that work comparably to currently available injectable medicines, ...
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the ...
Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its ...
The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound as the first treatment for a common ...
The battle for market share between the two leaders in the booming obesity drug sector has a new data point ...
Highly anticipated Phase 2 data for Amgen’s obesity drug show that on average, participants lost about 20% of their weight ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.